Individual usage of glucagon like peptide 1 receptor agonists reduced the risk of hospitalization due to alcohol and substance use disorders.

Metabolic dysfunction-associated steatotic liver disease (MASLD) is currently a pressing public health issue associated with ...

Glucagon-like peptide 1 receptor agonists and fenofibrates may protect patients with type 2 diabetes against diabetic macular ...

The term "nonalcoholic fatty liver disease" (NAFLD) has long been used to describe liver steatosis not related to excessive alcohol consumption ...

GLP-1 drugs are quickly becoming some of the most ubiquitous in the U.S., and they have drawn interest for their potential ...

Some people are not taking weight-loss medications responsibly, the physician says, and don't realize their full implications ...

New research found that some anti-obesity medications such as Wegovy and Zepbound may prompt people to drink less. These ...

Semaglutide use in diabetes patients is linked to a higher risk of NAION, a rare eye condition. A Danish-Norwegian study ...

The new guidance includes updates on diabetes technology use, GLP-1 receptor agonists, liver disease, drinking water, and ...

In addition, the decline in overall obesity rate reported by the CDC isn’t the first such drop. Between 1999 and 2018, the ...

GLP-1 agonists substantially slowed kidney deterioration and failure, independent of diabetes status. The most extensive and ...

Treatment with GLP-1RAs was associated with significant improvements in obstructive sleep apnea-related health outcomes.